Patents by Inventor Andrew J. Makoff

Andrew J. Makoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Expression of tetanus toxin fragment C in yeast
    Patent number: 5571694
    Abstract: Expression of tetanus toxin fragment C is accomplished employing a DNA coding sequence having a (G+C)-content that has been increased in the region from nucleotide 410 to the 3' end of the coding sequence relative to the wild-type DNA sequence. This allows the production of complete mRNA transcripts. Typically the (G+C)-content is increased in the following regions: (i) nucleotides 510-710, (ii) nucleotides 650-850, (iii) nucleotides 800-1100, (iv) nucleotides 900-1200 and (v) nucleotides 1100-1356. These regions in wild-type DNA encompass terminator sequences.
    Type: Grant
    Filed: July 25, 1994
    Date of Patent: November 5, 1996
    Assignee: Evans Medical Limited
    Inventors: Andrew J. Makoff, Michael A. Romanos, Jeffrey J. Clare, Neil F. Fairweather
  • Expression of tetanus toxin fragment C
    Patent number: 5443966
    Abstract: The present invention relates to an expression vector encoding mature fragment C of tetanus toxin. The invention further relates to an E. coli host transformed by that vector and to a process for producing mature fragment C of tetanus toxin using same.
    Type: Grant
    Filed: August 23, 1993
    Date of Patent: August 22, 1995
    Inventors: Neil F. Fairweather, Andrew J. Makoff
  • Expression of tetanus toxin fragment C in yeast
    Patent number: 5389540
    Abstract: Expression of tetanus toxin fragment C is accomplished employing a DNA coding sequence having a (G+C)-content that has been increased in the region from nucleotide 410 to the 3' end of the coding sequence relative to the wild-type DNA sequence. This allows the production of complete mRNA transcripts. Typically the (G+C)-content is increased in the following regions: (i) nucleotides 510-710, (ii) nucleotides 650-850, (iii) nucleotides 800-1100, (iv) nucleotides 900-1200 and (v) nucleotides 1100 to the 3' end of the coding sequence. The (G+C)-content may also be increased in the region of nucleotides 410-610. These regions in the wild-type DNA encompass terminator sequences.
    Type: Grant
    Filed: November 27, 1990
    Date of Patent: February 14, 1995
    Assignee: Evans Medical Limited
    Inventors: Andrew J. Makoff, Michael A. Romanos, Jeffrey J. Clare, Neil F. Fairweather